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With the ever increasing premiums placed on
novel therapies that arrive to market, it is no
surprise that many countries cannot afford to
approve such medicines whilst others place
stringent restrictions on their use.
Furthermore, most medicines are rarely
successful in all those individuals for whom
they are prescribed, with 60% of patients on
average initially deriving benefit [1]. Likewise,
in the longer term many patients lose the initial
benefit gained with the trigger factors
responsible for these ‘‘flares’’ largely unknown.
In addition to the unpredictability of adverse
events, it is no surprise that for several decades
research efforts have been made to try and
stratify therapies towards individuals and
populations they would truly benefit [2, 3]. In
the last several years, the treatments of
numerous cancers have been revolutionised by
molecular diagnostics. A classic example in
dermatology has been the discovery of the
BRAF mutation which occurs in approximately
50% of individuals with advanced malignant
melanoma. Those who express this mutation
will often have significant initial responses to
BRAF inhibitors. The longer-term benefits still
remain to be fully understood but are improved
by combined therapeutic approaches [4].
Cancers are accessible to such stratification as
mutations in cancer cells are frequent, can be
detected and then directly targeted. The
situation for inflammatory skin diseases is
more complex. For example, psoriasis as the
archetypal inflammatory dermatosis, is a
complex, multifactorial disease with interplay
between genetics and the environment.
Nonetheless, expensive biologic therapies are
now routinely prescribed in many parts of the
world for treating moderate–severe psoriasis.
Predicting response to these drugs in individual
patients is complex, such that stratification
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would be ideal to save money and unnecessary
drug exposure. A recent example in an
inflammatory condition, asthma, offers hope
that stratification may be possible. Thus, it was
demonstrated that a clinically relevant
biomarker (periostin) was associated with the
immunological pathway targeted by a specific
therapy (anti interleukin-13) [5]. In
dermatology, the target organ skin is accessible
and utilising new technologies to study RNA
transcripts expressed in psoriasis at early stages
of therapy may allow replication of the findings
in asthma. Further, bioinformatic methods to
allow integration of the large datasets produced
when studying ‘‘omics’’ are now well placed to
facilitate the interpretation of these data and
hopefully allow successful stratification of
biologic therapies [6].
Finally, from a cost perspective, the recent
approval by the European Medicines Agency
(EMA) of 2 biosimilar agents to infliximab has
opened up a whole new world of potential cost
containment drugs with many of our biologic
agents used in psoriasis, as well as in
rheumatology and gastroenterology likely to
lose patent protection over the ensuing
36 months. Rigid and expensive manufacturing
procedures and the appropriate monitoring of
‘‘biosimilarity’’ by agencies such as EMA & Food
and Drug Administration are likely to restrict
the number of companies having the
capabilities to bring these less expensive
biosimilar agents to market, to the current
pharmaceutical companies manufacturing and
marketing biologic agents [7].
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